Q-omics provides the consensus-scored RWDD3 profile across patient tissues and cancer cell-line models. RWDD3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RWDD3 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, RWDD3 RNA expression shows 20,112 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KICH, and ACC as cancer lineages where RWDD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RWDD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RWDD3 survival associations across molecular data types. RWDD3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RWDD3 RNA expression–survival associations across cancer types. High RWDD3 expression shows unfavorable associations in KIRP, LGG, LIHC, KIRC and ACC, but favorable associations in BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for RWDD3 RNA expression.
This table summarizes RWDD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RWDD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RWDD3 shows lower tumor expression in KICH, BRCA and THCA and higher tumor expression in LIHC, HNSC and CHOL. The KICH box plot shows higher RWDD3 RNA expression in normal versus tumor tissue (log2 FC = −1.210, t-test p < 0.001).
This table shows molecular features associated with RWDD3 in patient tissues and cancer cell lines. In patient samples, RWDD3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RWDD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
